【摘要】 目的研究巴曲酶治疗前循环脑梗死血浆纤维蛋白原(FIB)的动态变化及预后。方法将2005年11月～2008年5月入选的急性期前循环脑梗死患者150例随机分为巴曲酶组75例和对照组75例,观察两组用药前及首次用药后第3、5、7天血浆FIB定量和第3、6个月时的病死率、明显依赖生存状态及死亡/残疾。结果用药前两组FIB差异无统计学意义(P> 0.05);治疗后第3、5、7天,巴曲酶组FIB明显下降,差异有统计学意义(P <0.05)。两组病死率比较,差异无统计学意义(P> 0.05)。明显依赖生存率和死亡/残疾率3个月时两组差异无统计学意义(P> 0.05),两者6个月时巴曲酶组均好于对照组,差异有统计学意义(P <0.05)。两组均无症状性颅内出血,巴曲酶组颅外出血率比对照组高,差异有统计学意义(P <0.05)。结论巴曲酶能安全有效的降低前循环脑梗死患者血浆FIB,能明显改善患者的远期预后。更多还原

【Abstract】 Objective To study the dynamic changes and prognosis of plasma fibrinogen(FIB) in patients with anterior circulation cerebral infarction treated with batroxobin. Methods From November 2005 to May 2008,150 patients with acute precirculatory cerebral infarction were randomly assigned to the batroxacin group(75 cases) and the control group(75 cases).The plasma FIB quantification before treatment and 3,5,7 days after the first use of medicine,the mortality at the 3 rd,6 th month,obviously dependent on the survival state and death/disability were observed and compared between the two groups. Results There was no significant difference in FIB between the two groups before treatment(P > 0.05);On the 3 rd,5 th and 7 th day after treatment,FIB in batroxobin group decreased significantly as compared to those in the control group(P < 0.05).There was no significant difference in mortality between the two groups(P > 0.05).There was no significant difference in obviously dependent on the survival rate and death/disability rate between the two groups at 3 months(P > 0.05).While the batroxobin group was better in survival rate and death/disability rate than those in the control group at 6 months(P < 0.05).There was no symptomatic intracranial hemorrhage in both groups,and the rate of extracranial hemorrhage in batroxobin group was higher than that in the control group,and the difference was statistically significant(P < 0.05). Conclusion Batroxobin can reduce FIB in patients with anterior circulation cerebral infarction and improve the long-term prognosis of patients.更多还原